Go to the page content
Diabetes Obesity

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Locations

Not recruiting

Start date

05/11/2025

Identifiers

Trial ID NN9833-8243,
NCT number NCT07220759,
Eudract number Not Available

Summary

This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.

Trial Overview:

Condition

Overweight

Obesity

Type 2 Diabetes

Treatment

DRUG: Cagrilintide

DRUG: Placebo (matched to Cagrilintide)

Study type

INTERVENTIONAL

Trial duration

Nov 05 2025 - Jul 28 2027

Participants

330

Phase

III

Are you eligible?

Gender

Male and female

Age

18 years and older

Questions or concerns

Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.

This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.